Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide Vaccine
Clinical trial NCT03055000 · COMPLETED
Trial details
- NCT number
- NCT03055000
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-02-15
- Primary completion
- 2018-12-28
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.